Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study

被引：0

作者：

Kavanaugh, Arthur ^{[1
]}

Allanore, Yannick ^{[2
]}

Kucharz, Eugeniusz J. ^{[3
]}

Babic, Goran ^{[4
]}

机构：

[1] Univ Calif San Diego, Med, La Jolla, CA 92093 USA

[2] Paris Descartes Univ, Cochin Hosp, Dept Rheumatol, Paris, France

[3] Med Univ Silesia, Dept Internal Med & Rheumatol, Katowice, Poland

[4] Sandoz Co, Clin Dev, Biopharmaceut, Hexal AG, Holzkirchen, Germany

来源：

ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2797

引用

页数：2

共 50 条

[1] SWITCH BETWEEN REFERENCE ETANERCEPT (ETN) AND GP2015, AN ETANERCEPT BIOSIMILAR, DID NOT IMPACT EFFICACY AND SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: 48-WEEK RESULTS FROM THE PHASE 3 EQUIRA STUDY
Matucci-Cerinic, M.
Schulze-Koops, H.
Buch, M.
Kavanaugh, A.
Allanore, Y.
Kucharz, E. J.
Babic, G.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 609 - 609
[2] Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
Kavanaugh, Arthur
Matucci-Cerinic, Marco
Schulze-Koops, Hendrik
Buch, Maya
Allanore, Yannick
Kucharz, Eugeniusz J.
Babic, Goran
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[3] Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
Matucci-Cerinic, Marco
Allanore, Yannick
Kavanaugh, Arthur
Buch, Maya H.
Schulze-Koops, Hendrik
Kucharz, Eugeniusz J.
Woehling, Heike
Babic, Goran
Poetzl, Johann
Davis, Adanna
Schwebig, Arnd
RMD OPEN, 2018, 4 (02):
[4] EFFECTIVENESS AND SAFETY OF BIOSIMILAR ETANERCEPT GP2015 IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE UK: RESULTS FROM THE COMPACT STUDY
Askari, Ayman
Both, Charlotte
Martin, Angela
Walsh, David A.
Sheeran, Tom
RHEUMATOLOGY, 2024, 63 : I81 - I81
[5] Effectiveness and safety of biosimilar etanercept GP2015 in patients with rheumatoid arthritis in the UK: results from the COMPACT study
Askari, Ayman
Both, Charlotte
Martin, Angela
Walsh, David A.
Sheeran, Tom
RHEUMATOLOGY, 2024, 63
[6] Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
Carballo, Nuria
Perez Garcia, Carolina
Grau, Santiago
Monfort, Jordi
Duran-Jorda, Xavier
Echeverria-Esnal, Daniel
Ferrandez, Olivia
FRONTIERS IN PHARMACOLOGY, 2022, 13
[7] Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data
Atzeni, Fabiola
Gerratana, Elisabetta
Bongiovanni, Sara
Talotta, Rossella
Miceli, Gianfranco
Salaffi, Fausto
Sarzi-Puttini, Piercarlo
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (06): : 344 - 349
[8] PHARMACOKINETICS AND SAFETY OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR, AND ETANERCEPT ORIGINATOR PRODUCT IN HEALTHY MALE SUBJECTS: A RANDOMISED TWO-WAY CROSSOVER STUDY
Afonso, M.
Heinrich, S. Sanguino
Poetzl, J.
Woehling, H.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 234 - 234
[9] NON MEDICAL SWITCH FROM ETANERCEPT ORIGINATOR TO BIOSIMILAR GP2015 IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES
Colaci, M.
Aprile, M. L.
La Rosa, A.
Di Maggio, A.
Malatino, L.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1135 - 1135
[10] Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis
Griffiths, C. E.
Reich, K.
D, Thac, I
Gerdes, S.
Arenberger, P.
Kingo, K.
Weglowska, J.
Woehling, H.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S193 - S193

← 1 2 3 4 5 →